Social network
Investors - Ensuring sustainable growth
Investors - Ensuring sustainable growth

Investors

Ensuring sustainable growth

Tools content (print, share, increase/decrease text size):

 

IR Thematic Call on sarilumab

November 09, 2015

Sanofi and Regeneron hosted a conference call for the financial community on sarilumab during the upcoming American College of Rheumatology Annual (ACR) Meeting in San Francisco. The conference call included a presentation followed by a Q&A session.

Sarilumab is a fully-human monoclonal antibody directed against the IL-6 receptor (IL-6R). This investigational compound is currently in clinical development for Rheumatoid Arthritis. Sarilumab achieved primary efficacy endpoints across all completed pivotal Phase 3 studies, including for TARGET and ASCERTAIN. Data from these two studies were presented as oral presentations at ACR on November 8th.

 

Related Press releases

 

Right area:

Stock Market

IR mobile application

SANOFI IR - The Investor Relations Mobile Application

SANOFI IR is available on iPhone, iPad, Apple Watch and Android!
NEW - Section dedicated to Individual Shareholders

 

Your services

 

© Sanofi 2004-2017 - All rights reserved - Update: November 29, 2016

  • Site complies with W3C WCAG 2.0 (new window, in english)